Vaxcyte surges 25.6% in pre-market; pneumococcal vaccine meets late-stage trial target

智通财经2026/10/05 10:32

Show original

Vaxcyte's stock price surged 25.6% in pre-market trading in the US, after the company's pneumococcal vaccine achieved its late-stage clinical trial goals.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vaxcyte shares surged 25.6% in pre-market trading in the US stock market, after the company’s pneumococcal vaccine achieved its late-stage clinical trial goals.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vaxcyte surges 25.6% in pre-market; pneumococcal vaccine meets late-stage trial target

You may also like

Crypto prices